Nuwellis forms Pediatric Advisory Board to advance Vivian™ pediatric CRRT system development

Nuwellis, Inc. announced it will convene a Pediatric Medical & Nursing Advisory Board in November 2026 to support the development of Vivian™, its next-generation pediatric continuous renal replacement therapy (CRRT) system designed for children as small as 2.5 kg. The advisory board includes experts from 11 leading U.S. pediatric institutions who will provide feedback to refine the system’s design and clinical workflow. This initiative is part of Nuwellis’ broader pediatric strategy, which also includes seeking regulatory approval to expand the use of its Aquadex SmartFlow system to pediatric patients weighing 5 kg or more. These efforts aim to address unmet needs in pediatric fluid management and renal support with specialized technology.

Nuwellis Inc (NUWE) trades at USD 0.68 on Pluang, with a market cap of $2.20M as of Oct 08, 2026 19:43 WIB. The stock shows a 1-day decline of 1.53%, while order activity is nearly balanced with 52% selling and 48% buying interest. This trading pattern comes as the company advances its pediatric therapy technology with the upcoming advisory board meeting.